NEW YORK (TheStreet
) -- CHANGE IN RATINGS
AEO upgraded at Sterne Agee to Buy. $27 price target. Estimates also boosted, as new management initiatives should drive growth.
AMD upgraded at Goldman from Sell to Neutral, Goldman Sachs said. Valuation call, as the stock is down 49% over the past year. $3.50 price target.
AMGN upgraded at UBS from Neutral to Buy, UBS said. $96 price target. Expect better near-term clinical data.
ARIA upgraded at BofA/Merrill from Neutral to Buy, Bank of America/Merrill Lynch said. $26 price target. Expect continued strong clinical data in the near term.
BIIB downgraded at UBS from Buy to Neutral, UBS said. $156 price target. Valuation call, as the stock is up 56% from the last upgrade.
BMS rated new Neutral at JPMorgan. $37 price target. Lagging fundamentals balance cash generation story.
Brocade Communications Systems
BRCD upgraded to buy at TheStreet Ratings.
CLNY downgraded to hold at TheStreet Ratings.
CELG downgraded at UBS from Buy to Neutral, UBS said. $80 price target. Valuation call, as the stock is up 27% since Revlimid was not approved in the EU.
CLF downgraded at Goldman from Buy to Neutral, Goldman Sachs said. $39 price target. Estimates also cut, given lower expected iron ore prices and rising costs.
CRS upgraded at JPMorgan to Overweight from Neutral, JPMorgan said. $70 price target. Sustainable growth in materials.
DOV upgraded at JP Morgan from Underweight to Neutral, JP Morgan said. Valuation call.
DOX downgraded at Jefferies to Hold from Buy, Jefferies said. $35 price target. Full valuation.
EXC downgraded at Citigroup from Neutral to Sell, Citigroup said. $31 price target. Estimates also cut, given higher expected costs.
Fifth Third Bancorp
FITB downgraded at Oppenheimer to Perform from Outperform, Oppenheimer said. Catalyst achieved.
FULT upgraded at Sterne Agee to Buy from Hold, Sterne Agee said. $11.50 price target. Attractive valuation.
HUB.B downgraded at JP Morgan from Overweight to Neutral, JP Morgan said. Stock is already factoring in a late-stage economic recovery.
IP downgraded at Deutsche from Buy to Hold, Deutsche Bank said. $39 price target. Stock is already pricing in a potential price hike, which may not yet materialize.
MCO upgraded at Lazard to Buy from Neutral, Lazard said. $52 price target. Company is leveraged to high debt issuance rates.
NEE upgraded at Wells from Market Perform to Outperform, Wells Fargo said. Stock is attractive, following the recent rotation out of utility stocks.
NRG upgraded at Goldman from Neutral to Buy, Goldman Sachs said. $25 price target. Texas should drive growth and the company generates solid free cash flow.
PKG downgraded at Goldman from Buy to Hold, Goldman Sachs said. $34 price target. Valuation call, as the sector has made a strong move over the past several weeks.
PNC Financial Services Group
PNC upgraded at Oppenheimer to Outperform from Perform, Oppenheimer said. $75 price target. Acquisition of RBC Bank (USA) is an ideal platform.
PPG upgraded at Jefferies to Buy from Hold, Jefferies said. $135 price target. Taking the right steps.
RKT downgraded at Deutsche from Buy to Hold, Deutsche Bank said. Valuation call, based on a $75 price target.
S upgraded at Nomura from Neutral to Buy, Nomura said. $7 price target. Company is cutting costs and fears of increased competition have been overblown.
SEE rated new Overweight at JPMorgan. $19 price target. Cheap on legacy FCF with upside.
SLXP rated new Market Perform at Leerink. Uncertainty surrounds Relistor and the company lacks near-term catalysts.
SUSQ downgraded at Sterne Agee from Buy to Neutral, Sterne Agee said. Valuation call, as the stock is up 31% year-to-date.
TYC downgraded at JP Morgan from Overweight to Neutral, JP Morgan said. Valuation call.
STOCK COMMENTS / EPS CHANGES
AIRM target raised at Oppenheimer.
Shares of AIRM now seen reaching $130, Oppenheimer said. Bullish following meetings with management. Outperform rating.
CLH numbers cut at Credit Suisse.
Shares of CLH now seen reaching $65. Estimates also reduced, given lower expected oil service margins. Outperform rating.
ENDP added to US 1 List at BofA/Merrill.
ENDP was placed on the US 1 list, Bank of America/Merrill Lynch said. Opana ER market share should soon recover. Buy rating and $40 price target.
FMC numbers raised at Jefferies.
Shares of FMC now seen reaching $66, Jefferies said. Estimates also raised on greater emphasis on organic growth. Buy rating.
INTC estimates, target reduced at JMP.
INTC estimates were cut through 2013, JMP Securities said. Company lowered its guidance. Outperform rating and new $30 price target.
LULU estimates, target raised at Nomura.
Shares of LULU now seen reaching $62, according to Nomura. Estimates also increased, as the company is realizing a lower tax rate. Neutral rating.
RF added to Conviction Buy List at Goldman. Company can continue to cut costs to right-size the business.
URBN added to US 1 List at BofA/Merrill. Comp sales growth should continue to turn around. Buy rating and $45 price target.
WFC cut from Conviction Buy List at Goldman. Valuation call.
WSM numbers increased at Citi.
WSM estimates were raised through 2014, Citigroup said. Expect higher back-to-school sales. Buy rating and new $49 price target.
>To submit a news tip, email: email@example.com
READERS ALSO LIKE:
and become a fan on Facebook.
For less than $3 per week, you can get full access to Jim Cramer's intraday market commentary and stock trading strategies - sometimes before he says them on TV! Join now.